288 research outputs found
A new woodrat from southwestern Arizona and a new rock pocket-mouse from northwestern Sonora
http://deepblue.lib.umich.edu/bitstream/2027.42/56712/1/OP273.pd
Treatment of Kaposi Sarcoma-Associated Herpesvirus-Associated Cancers
Kaposi sarcoma (KS) is the most frequent AIDS-defining cancer worldwide. KS-associated herpesvirus (KSHV) is the etiological agent of KS, and the virus is also associated with two lymphoproliferative diseases. Both KS and KSHV-associated lymphomas, are cancers of unique molecular composition. They represent a challenge for cancer treatment and an opportunity to identify new mechanisms of transformation. Here, we review the current clinical insights into KSHV-associated cancers and discuss scientific insights into the pathobiology of KS, primary effusion lymphoma, and multicentric Castleman’s disease
Determinants of mTOR inhibitor therapy in AIDS-associated malignancies
Rapamycin/Sirolimus™ leads to the regression of transplant-
associated Kaposi sarcoma (KS). It also leads to
disease stabilization in HIV-associated KS. Case reports
and a wealth of preclinical studies support rapamycin’s
efficacy also in AIDS associated lymphoma, such as primary
effusion lymphoma (PEL). Rapamycin inhibits the
mammalian target of rapamycin (mTOR) and papamycin
derivatives are approved for the treatment of mantle
cell lymphoma and other cancers. It is not universally
effective against all solid tumors. Even within this group
of clinically responsive cancers, there are exceptions of
cases or cell models in which this drug or its derivatives
(rapalogs) fail
AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
As an obligate intracellular parasite, Kaposi sarcoma-associated herpesvirus (KSHV) relies on the host cell machinery to meet its needs for survival, viral replication, production, and dissemination of progeny virions. KSHV is a gammaherpesvirus that is associated with three different malignancies: Kaposi sarcoma (KS), and two B cell lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease. KSHV viral proteins modulate the cellular phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway, which is a ubiquitous pathway that also controls B lymphocyte proliferation and development. We review the mechanisms by which KSHV manipulates the PI3K/AKT/mTOR pathway, with a specific focus on B cells
AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
As an obligate intracellular parasite, Kaposi sarcoma-associated herpesvirus (KSHV) relies on the host cell machinery to meet its needs for survival, viral replication, production, and dissemination of progeny virions. KSHV is a gammaherpesvirus that is associated with three different malignancies: Kaposi sarcoma (KS), and two B cell lymphoproliferative disorders, primary effusion lymphoma (PEL) and multicentric Castleman’s disease. KSHV viral proteins modulate the cellular phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway, which is a ubiquitous pathway that also controls B lymphocyte proliferation and development. We review the mechanisms by which KSHV manipulates the PI3K/AKT/mTOR pathway, with a specific focus on B cells
Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas
Non-Hodgkin lymphoma (NHL) are a diverse group of hematological malignancies comprised of over 60 subtypes. These subtypes range from indolent to aggressive. The PI3K/Akt/mTOR pathway has been shown to contribute to cell survival and proliferation and is constitutively active in most NHL. MK-7075 (miransertib) and MK-4440 are small molecules that effectively inhibit Akt and have entered clinical development. Using in vitro and in vivo models of NHL, we explored targeting the kinase Akt with miransertib and MK-4440 alone or in combination with the mTORC1 inhibitor, rapamycin (sirolimus). Both Akt inhibitors inhibited the pathway and NHL proliferation in a subtype-dependent manner. However, these compounds had a minimal effect on the viability of primary B-cells. Importantly, the combination of miransertib and sirolimus synergistically reduced cell proliferation in NHL, including in one indolent subtype, e.g., follicular lymphoma (FL), and two aggressive subtypes, e.g., diffuse large B-cell lymphoma (DLBCL) and primary effusion lymphoma (PEL). To establish in vivo efficacy, we used several xenograft models of FL, DLBCL, and PEL. The results obtained in vivo were consistent with the in vitro studies. The FL xenograft was highly sensitive to the inhibition of Akt alone; however, the tumor burden of PEL xenografts was only significantly reduced when both Akt and mTORC1 were targeted. These data suggest that targeting the PI3K/Akt/mTOR pathway with Akt inhibitors such as miransertib in combination with mTOR inhibitors serves as a broadly applicable therapeutic in NHL
Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)—an update
Kaposi sarcoma-associated herpesvirus (KSHV) is the etiological agent of several human malignancies. The virus is able to modulate pro-proliferative pathways to its advantage, while simultaneously inhibiting pro-apoptotic signaling pathways. These functions are carried out by multiple viral proteins acting in concert. The overall outcome is the survival and proliferation of the infected cell. Additionally, the virus also modulates innate immune pathways to allow for prolonged survival of the infected cell following primary infection, and during viral latency. Here we review the latest advances in our knowledge of KSHV pathogenesis
Kaposi sarcoma–associated herpesvirus: immunobiology, oncogenesis, and therapy
Kaposi sarcoma–associated herpesvirus (KSHV), also known as human herpesvirus 8, is the etiologic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman’s disease. This human gammaherpesvirus was discovered in 1994 by Drs. Yuan Chang and Patrick Moore. Today, there are over five thousand publications on KSHV and its associated malignancies. In this article, we review recent and ongoing developments in the KSHV field, including molecular mechanisms of KSHV pathogenesis, clinical aspects of KSHV-associated diseases, and current treatments for cancers associated with this virus
Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers
Kaposi's sarcoma-associated herpesvirus (KSHV) is linked
to three different human cancers: Kaposi's sarcoma (KS),
primary effusion lymphoma (PEL) and multicentric Castleman's
disease (MCD). We have previously reported that
the PI3K/Akt/mTOR pathway is critical for the survival of
KSHV-infected endothelial cells and B cells, and have
demonstrated that Rapamycin/Sirolimus, an inhibitor of
mTOR, can induce PEL cell death in vitro and in vivo (Sin
et al., Blood. 2007. 109(5):2165–73). We have now
extended these findings and demonstrate that therapeutic
targeting of other members of the PI3K/Akt/mTOR signal
transduction pathway can also induce cell death in PEL in
vitro and inhibit tumor growth in murine xenograft models.
Importantly, some of these novel drug candidates
have passed clinical trials for other indications and can
therefore be tested for efficacy against KS and AIDS-associated
lymphomas
The K1 Protein of Kaposi's Sarcoma-Associated Herpesvirus Augments Viral Lytic Replication
ABSTRACT The K1 gene product of Kaposi's sarcoma-associated herpesvirus (KSHV) is encoded by the first open reading frame (ORF) of the viral genome. To investigate the role of the K1 gene during the KSHV life cycle, we constructed a set of recombinant viruses that contained either wild-type (WT) K1, a deleted K1 ORF (KSHVΔK1), stop codons within the K1 ORF (KSHV-K1 5×STOP ), or a revertant K1 virus (KSHV-K1 REV ). We report that the recombinant viruses KSHVΔK1 and KSHV-K1 5×STOP displayed significantly reduced lytic replication compared to WT KSHV and KSHV-K1 REV upon reactivation from latency. Additionally, cells infected with the recombinant viruses KSHVΔK1 and KSHV-K1 5×STOP also yielded smaller amounts of infectious progeny upon reactivation than did WT KSHV- and KSHV-K1 REV -infected cells. Upon reactivation from latency, WT KSHV- and KSHV-K1 REV -infected cells displayed activated Akt kinase, as evidenced by its phosphorylation, while cells infected with viruses deleted for K1 showed reduced phosphorylation and activation of Akt kinase. Overall, our results suggest that K1 plays an important role during the KSHV life cycle. IMPORTANCE Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of three human malignancies, and KSHV K1 is a signaling protein that has been shown to be involved in cellular transformation and to activate the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway. In order to investigate the role of the K1 protein in the life cycle of KSHV, we constructed recombinant viruses that were deficient for K1. We found that K1 deletion viruses displayed reduced lytic replication compared to the WT virus and also yielded smaller numbers of infectious progeny. We report that K1 plays an important role in the life cycle of KSHV
- …